Laura Stiles

Lofexidine may expand the treatment options available for managing withdrawal when buprenorphine and methadone are unavailable or undesirable.

Borderline personality disorder, a disorder that is often misunderstood by the general public, also raises questions for psychiatrists.

At 6 weeks of treatment, severely ill patients treated with adjunctive brexpiprazole had a greater reduction in PANSS total scores and CGI-S scores compared with those receiving placebo.

This research provides further support to compelling data linking inflammation and depression.

The researchers believe this study is the first to detect a statistically significant, unexpected inverse association between efavirenz use and depression.

The researchers found significant advantages from dialectical behavior therapy in all primary outcomes.

The Janssen Pharmaceutical Companies of Johnson & Johnson have announced the results of 2 long-term phase 3 clinical trials examining esketamine nasal spray in patients with treatment-resistant depression.

Widespread use of antidepressants may be contributing to long-term increased risk for weight gain.

Dr Stewart has held executive leadership positions in public behavioral health systems in Michigan, New York, and Pennsylvania. Her career has spanned 3 decades in public sector administration.

This study had a sample size large enough to assess the effect of circadian disruption on mental health disorders, and was the first to objectively measure patterns of rest and activity (using accelerometers).

Electroconvulsive therapy (ECT) has been used for refractory psychiatric conditions in the United States since 1938. Despite this, few practitioners are comfortable recommending ECT for minors.

The primary outcomes assessed were the differences in clinically assessed depressive and manic symptoms, as well as the rate of depressive and manic episodes.

The average MADRS-10 scores decreased from baseline, and this decrease was maintained at the end of the study.

By bringing together published and unpublished data from more than 500 double-blind, randomized, controlled trials, this study represents the best currently available evidence base to guide the choice of pharmacologic treatment for adults with acute depression.

Use of virtual reality environments in which participants interact with computer-controlled situations or avatars enables a more fine-tuned approach to exposure in the context of cognitive behavioral therapy.

Findings suggest that children with BECTS is predictive of neuropsychological outcomes, not age of first seizure.

The ability to track ingestion of medications prescribed for mental illness may be useful for some patients.

Results indicate there is an unmet need for better treatment to manage symptom burden in US adults with ADHD.

The PANS/PANDAS guidelines contain 3 parts: (1) psychiatric and behavioral interventions, (2) immunomodulatory therapies, and (3) treatment and prevention of infections.

Impaired recollection could be a vulnerability marker for schizophrenia, whereas impaired social context memory could be a disease-related marker.

A high percentage of patients were persistent and adherent to their PP3M treatment.

A significant improvement in depressive symptoms was measured using validated rating scales.

Long-acting injectables should be considered earlier in the treatment of schizophrenia.

Child maltreatment is significantly more prevalent in young individuals who present with UHR symptoms compared with controls.

In bipolar disorder, neurocognitive impairment needs to be considered a therapeutic clinical target to improve psychosocial functioning.

In cases of PTSD in children, reports showed a marked improvement in nightmares when prazosin was prescribed.

Neither bipolar disorder nor lithium treatment was associated with increased cancer incidence.

Long-term valbenazine may be beneficial in managing tardive dyskinesia.

Enlarged self-perceived areas of pain may be perceived as poorer health status by patients, making the emotional burden worse.

Patients matched to their preferred treatment were more likely to complete the trial but not more likely to achieve depression remission.